Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Zydus Lifesciences, Sunshine Healthcare advance Sri Lanka pharmaceutical manufacturing deal
Zydus Lifesciences and Sunshine Healthcare have signed an investment agreement for a pharmaceutical manufacturing facility in Sri Lanka. Production is targeted for 2028, while completion of the proposed joint venture's ownership structure remains pending.
Ironwood Pharmaceuticals (Nasdaq: IRWD) names Tammi Gaskins CEO as LINZESS profits rise
Ironwood Pharmaceuticals has appointed Chief Commercial Officer Tammi Gaskins to succeed Tom McCourt as Chief Executive Officer from January 2027. The succession follows a major 2025 workforce reduction and arrives after sharply stronger LINZESS economics restored profitability, leaving Gaskins to balance cash generation with the late-stage development of apraglutide.
Mesoblast (ASX: MSB) reports US$99m cash after stronger Ryoncil sales and lower expenditure
Mesoblast has reported higher year-on-year revenue from its approved cell therapy Ryoncil and a sharp reduction in operating cash expenditure, although sequential sales declined following a stronger June quarter.
BIOxHEAL Phase 3 trial puts Applied Biologics’ advanced wound-care strategy in focus
Applied Biologics begins Phase 3 BIOxHEAL testing for diabetic foot ulcers. Discover its commercial potential, regulatory risks and market outlook.
Entera Bio’s next big opportunity: Can its oral osteoporosis treatment transform a market dominated by injections?
Entera Bio's EB613 osteoporosis results strengthen its Phase 3 outlook. Explore the $275M financing, stock reaction and commercial potential.
Enliven Therapeutics appoints Kristine Ball as $895m-backed leukemia Phase 3 trial nears
Enliven Therapeutics has expanded its board and appointed a new audit committee member as it prepares to initiate a pivotal 450-patient study of relcobatinib before the end of 2026. With FDA alignment secured on the trial design and substantial cash reserves, attention is shifting towards clinical execution, competitive differentiation and eventual commercial readiness.
Vanda Pharmaceuticals VQW-765 fails Phase 3 anxiety trial as stock faces fresh pressure
Vanda Pharmaceuticals has paused development of VQW-765 after a 546-patient Phase 3 study failed to demonstrate a significant reduction in social anxiety symptoms. The setback removes a near-term clinical catalyst, placing greater importance on its commercial product launches, cash position and remaining regulatory milestones.
Shenandoah Therapeutics appoints Steve Worland CEO as BCL6 cancer program nears IND studies
Shenandoah Therapeutics has appointed biotechnology veteran Steve Worland as chief executive officer, with co-founder Isabella Graef moving into the chief scientific officer role. The leadership change comes as the company's BCL6-targeting oncology program approaches IND-enabling studies, creating an important test of its transcriptional and epigenetic drug discovery platform.
First Tracks Biotherapeutics delivers major ANB033 trial win as celiac drug competition intensifies
First Tracks Biotherapeutics stock jumps on positive ANB033 celiac disease trial data. Discover what the results mean for investors and its growth outlook.
Chipscreen Biosciences wins China IND approval for CS43158, putting AML resistance strategy to the test
China's approval of clinical testing for CS43158 opens a new development opportunity for Chipscreen Biosciences in acute myeloid leukemia, but its ambitious multikinase approach must now demonstrate meaningful benefits beyond existing FLT3-targeted treatments.